Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Hard capsule compound containing dutasteride and tamsulosin and preparation method thereof

A technology of dutasteride and hard capsules, which is applied in the directions of medical preparations containing active ingredients, microcapsules, capsules, etc., can solve the problems of reducing the rapid action of dutasteride and poor drug compliance, and improve drug compliance. The effect of stability, fast drug effect, high initial dissolution rate

Active Publication Date: 2022-01-07
HANMI PHARMA
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Jalyn's hard capsules have a very large size: size 00, so drug compliance among elderly patients is poor, and its initial dissolution rate of dutasteride is lower than that of a single dutasteride formulation, which tends to To reduce the rapid action of dutasteride

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hard capsule compound containing dutasteride and tamsulosin and preparation method thereof
  • Hard capsule compound containing dutasteride and tamsulosin and preparation method thereof
  • Hard capsule compound containing dutasteride and tamsulosin and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] Embodiment 1: prepare hard capsule compound preparation (1)

[0095] Prepare a separate dutasteride portion and a separate tamsulosin portion according to the following prescription:

[0096] -Independent dutasteride moiety-

[0097]

[0098] -Separate Tamsulosin section-

[0099]

[0100]

[0101] Separate dutasteride fractions were prepared by dissolving dutasteride in monoglyceride oil and diglyceride oil, adding thereto all remaining components, and dissolving the mixture to prepare a self-emulsifying emulsion. The prepared self-emulsifying emulsion was filled into soft capsules to prepare dutasteride soft capsules. In detail, the coating composition was prepared using a capsule base material having a weight ratio of 81:46:1 gelatin:glycerol:glycine according to a conventional method for preparing a coating. Next, according to the conventional filling method, use the rotary automatic filling machine to fill the prepared self-emulsifying emulsion into 2...

Embodiment 2

[0104] Embodiment 2: prepare hard capsule compound preparation (2)

[0105]Tamsulosin granules were prepared in the same manner as in Example 1, which were then further mixed with 9 mg (5%) of crospovidone as a disintegrant, followed by tableting by a circular punch with a diameter of 6.5 mm . The obtained tamsulosin tablets and dutasteride soft capsules were filled into size 0 gelatin hard capsules (SUHEUNG Co., Ltd.) to prepare a capsule composite preparation.

Embodiment 3

[0106] Embodiment 3: prepare hard capsule compound preparation (3)

[0107] An independent dutasteride part was prepared in the same manner as in Example 1, and an independent tamsulosin part was prepared by the following prescription:

[0108] -Separate Tamsulosin section-

[0109]

[0110] Separate tamsulosin fractions were prepared by mixing all listed tamsulosin hydrochloride, microcrystalline cellulose, hypromellose and 6.0 mg talc in powder form and using A binder solution prepared by dissolving acrylic acid-ethyl acrylate copolymer in water to prepare particles. Next, the prepared tamsulosin granules were coated with an enteric coating solution by dissolving 7.0 mg of methacrylic acid-ethyl acrylate copolymer, triacetin and 3.0 mg of talc in prepared in water to prepare tamsulosin hydrochloride granules. Sucrose stearate was added thereto and mixed therewith to prepare tamsulosin granules.

[0111] The obtained tamsulosin granules and dutasteride soft capsules ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

One aspect of the present disclosure provides a hard capsule compound and a preparation method thereof, the hard capsule compound comprising in a separate state: an independent part of dutasteride, the part comprising dutasteride or its pharmaceutically acceptable and an independent part of tamsulosin, which part comprises tamsulosin or a pharmaceutically acceptable salt thereof, wherein the independent part of dutasteride is composed of dutasteride, oil and surfactant The formulation of self-emulsifying emulsion; the independent part of tamsulosin is a solid preparation containing a sustained-release agent; the independent part of dutasteride and the independent part of tamsulosin are contained in a separate state and can be filled into capsules size 0 to 3.

Description

technical field [0001] The present disclosure relates to a hard capsule composite formulation comprising dutasteride and tamsulosin as active ingredients, more specifically, the present invention relates to a hard capsule composite formulation comprising dutasteride and tamsulosin and preparation of the hard capsule A method of composite formulation, wherein the hard capsule composite formulation exhibits the rapid onset efficacy of dutasteride and has improved drug compliance by having a reduced size. Background technique [0002] Benign prostatic hyperplasia is one of the typical diseases that occurs frequently in men aged 50 years or older, causing difficulty urinating due to the enlargement of the prostate gland. Benign prostatic hyperplasia can also cause complications, such as urinary tract infection, urolithiasis, hematuria, and renal failure. [0003] Dutasteride is a 5-α reductase inhibitor (chemical name: 17β-N-(2,5-bis(trifluoromethyl))phenylcarbamoyl-4-aza-5α-an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/48A61K9/50A61K31/58A61K31/18
CPCA61K9/48A61K9/50A61K31/18A61K31/58A61K9/4808A61K9/4825A61K9/4833A61K9/5057A61K9/5084
Inventor 李炳俊金唇哲金载镐金用镒朴宰贤禹钟守
Owner HANMI PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com